- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celldex Therapeutics Inc (CLDX)
Celldex Therapeutics Inc stock price live, this page displays NASDAQ CLDX stock exchange data. View the CLDX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Celldex Therapeutics Inc real time stock price chart below.
What Is the Celldex Therapeutics Inc Stock Price Today?
The Celldex Therapeutics Inc stock price today is 21.86.
What Is the Stock Symbol for Celldex Therapeutics Inc?
The stock symbol for Celldex Therapeutics Inc is ""CLDX.""
What Stock Exchange Does Celldex Therapeutics Inc Trade On?
Celldex Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Celldex Therapeutics Inc a Good Stock to Buy?
Determining whether Celldex Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLDX quote. (ISIN: US15117B2025)
What Is the Celldex Therapeutics Inc Stock Price Today?
The Celldex Therapeutics Inc stock price today is 21.86.
What Is the Stock Symbol for Celldex Therapeutics Inc?
The stock symbol for Celldex Therapeutics Inc is ""CLDX.""
What Stock Exchange Does Celldex Therapeutics Inc Trade On?
Celldex Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Celldex Therapeutics Inc a Good Stock to Buy?
Determining whether Celldex Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLDX quote. (ISIN: US15117B2025)
NASDAQ
Currency in USD
21.86
-0.33(-1.49%)
Real-time Data·
Fair Value
An estimate of a Celldex Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.66
22.28
52 wk Range
14.40
47.00
CLDX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 3 days
More Info
Fair Value
An estimate of a Celldex Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.6622.28
52 wk Range
14.4047.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLDX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Celldex Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
58.54
Upside
+167.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Celldex Therapeutics Inc Company Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Celldex Therapeutics Inc SWOT Analysis
Barzolvolimab's Promise | Explore barzolvolimab's potential in treating chronic inflammatory conditions, with projected peak sales of $1 billion for eosinophilic esophagitis alone |
Financial Health | Celldex boasts a robust cash position of $673 million, supporting operations through 2027, despite recent stock volatility and analyst targets ranging from $31 to $90 |
Pipeline Progression | Anticipate crucial data releases for barzolvolimab in EoE and CSU, alongside the development of CDX-622, a promising bispecific antibody for various inflammatory conditions |
Market Dynamics | Delve into Celldex's competitive landscape, including the impact of generic Xolair and the company's strategy to address unmet needs in treatment-resistant patients |
Compare CLDX to Peers and Sector
Metrics to compare | CLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.1x | 1.8x | −0.5x | |
PEG Ratio | −1.91 | 0.00 | 0.00 | |
Price/Book | 2.1x | 2.3x | 2.6x | |
Price / LTM Sales | 191.3x | 6.5x | 3.3x | |
Upside (Analyst Target) | 161.4% | 282.3% | 45.1% | |
Fair Value Upside | Unlock | 24.5% | 7.4% | Unlock |
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 58.54
(+167.79% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.81 / -0.74
Revenue / Forecast
695.00K / 1.42M
People Also Watch
FAQ
What Stock Exchange Does Celldex Therapeutics Trade On?
Celldex Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Celldex Therapeutics?
The stock symbol for Celldex Therapeutics is "CLDX."
What Is the Celldex Therapeutics Market Cap?
As of today, Celldex Therapeutics market cap is 1.45B.
What Is Celldex Therapeutics's Earnings Per Share (TTM)?
The Celldex Therapeutics EPS (TTM) is -2.70.
When Is the Next Celldex Therapeutics Earnings Date?
Celldex Therapeutics will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is CLDX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Celldex Therapeutics Stock Split?
Celldex Therapeutics has split 2 times.
How Many Employees Does Celldex Therapeutics Have?
Celldex Therapeutics has 186 employees.
What is the current trading status of Celldex Therapeutics (CLDX)?
As of 04 Aug 2025, Celldex Therapeutics (CLDX) is trading at a price of 21.86, with a previous close of 22.19. The stock has fluctuated within a day range of 21.66 to 22.28, while its 52-week range spans from 14.40 to 47.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.